Greenstone Biosciences
Greenstone Biosciences speeds drug discovery by using human induced pluripotent stem cells (iPSCs) and computational methods to model disease and identify therapies. The company combines curated patient- and disease-specific iPSC lines with AI, computational biology, and pharmacogenomics to run high-fidelity disease models and evaluate targets and compounds. Its platform operates as a biotech drug-discovery platform serving academic researchers and industry partners, and the company supplies iPSCs for research use. Greenstone integrates experimental iPSC-based assays with machine learning-driven analytics to prioritize therapeutic candidates. The approach targets pharmaceutical and biotech customers seeking preclinical disease models, target validation, and personalized-treatment insights.
Greenstone Biosciences
Greenstone Biosciences speeds drug discovery by using human induced pluripotent stem cells (iPSCs) and computational methods to model disease and identify therapies. The company combines curated patient- and disease-specific iPSC lines with AI, computational biology, and pharmacogenomics to run high-fidelity disease models and evaluate targets and compounds. Its platform operates as a biotech drug-discovery platform serving academic researchers and industry partners, and the company supplies iPSCs for research use. Greenstone integrates experimental iPSC-based assays with machine learning-driven analytics to prioritize therapeutic candidates. The approach targets pharmaceutical and biotech customers seeking preclinical disease models, target validation, and personalized-treatment insights.
TL;DR
Headquarters & founding: Founded 2021; based in Stanford Research Park (Palo Alto, CA)
Core tech: Human iPSC-based NAMs, 3D organoids, high-throughput assays, AI/computational biology
Product / customers: Biotech drug-discovery platform serving pharma/biotech and academic researchers; supplies iPSC lines for research use
Biobank: Maintains an iPSC biobank of >2,000 lines (patient-derived and controls)
Funding signal: Grant funding from public research bodies including NIH and CIRM
Company Overview
Problem Domain
Preclinical drug discovery and target validation using human-relevant experimental models
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
Investor Signal
“Backed by public research funders and life-science investors; engages institutional investors and strategic partners”